NICE recommends phased roll out of genetic testing for clopidogrel prescribing
In draft guidance, the National Institute for Health and Care Excellence said that testing could be rolled out to patients at higher risk of stroke recurrence first, while capacity is established.
NICE said the roll out of CYP2C19 genotype laboratory testing could occur “in a stepwise process”
Shutterstock.com
The National Institute for Health and Care Excellence (NICE) has recommended that a pharmacogenomic test to assess whether patients at risk of stroke should be treated with clopidogrel should be “phased” in to address concerns around testing capacity.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
